Search Within
Applications
Content Type
Vaccine manufacturing
Applied Filters:
facet applications:Vaccine manufacturing
Showing 1-19 of 19 results
mRNA Vaccines and Therapeutics Manufacturing
mRNA vaccine technology offers rapid development and scalable manufacturing for disease prevention.
Egg-based and Cell-based Influenza Vaccine Manufacturing Methods
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
Cell Harvest, Lysis, Neutralization and Clarification of Plasmid DNA (pDNA) for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications
An overview of the cell harvest, lysis, neutralization, and clarification steps used for pDNA purification along with case study and practical advice.
Vaccine Manufacturing
From early phase development, through downstream purification to large scale vaccine production: learn more about vaccine process development and application expertise.
Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps
This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.
Protein Subunit Vaccine Manufacturing
This page provides an overview of protein subunit vaccines, which incorporate a recombinant protein fragment derived from the viral pathogen. It includes a description of the subunit vaccine manufacturing workflow and the products and technologies that are essential to ensure
Manufacturing Strategies for mRNA Vaccines and Therapeutics
mRNA technology uses non-viral delivery systems and offers a great deal of versatility. Delivery of an mRNA into the cytosol of a cell can induce the production of a target protein which can function as a therapeutic or prophylactic, act
Choosing the optimal cell culture media for vaccine production
Choosing the optimal cell culture media for vaccine production
Choosing the optimal cell culture media for vaccine production
Choosing the optimal cell culture media for vaccine production
Choosing the optimal cell culture media for vaccine production
Choosing the optimal cell culture media for vaccine production
Vaccine Development Platforms
Compare novel technologies, manufacturing considerations, and case studies for virus-like-particles, viral vectors, plasmid DNA, and mRNA platforms in webinar.
mRNA Synthesis for the Development of Vaccines and Therapeutics
Understand how mRNA vaccines induce immunity. and read how synthetic mRNA is prepared for vaccine immunogens and other biopharmaceuticals. Find reagents for synthesis of mRNA.
Plasmid DNA (pDNA) Manufacturing Process: Downstream Purification
Get a step-by-step overview of the plasmid DNA manufacturing process and the challenges in pDNA downstream purification. Read our free pDNA downstream purification eBook for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications.
Virus-Based Vaccine Manufacturing
Manufacturing viral vaccines is complex and there is no templated approach. Each process must be tailored to the shape, size, nature, physico-chemical behavior, stability, and host specificity of the virus. Learn all about this core platform technology and how expertise—empowered
Plasmid DNA Vaccines Manufacturing
Manufacturing plasmid DNA (pDNA) vaccines is challenging due to low productivity of fermentation and the large size and negative charge of the plasmid. The lysate can also be highly viscous with contaminants similar to pDNA leading to low resolution separation.
Virus-like Particles (VLPs) Vaccine Manufacturing
VLP vaccine manufacturers must optimize upstream productivity with reliable scale-up, achieve yield and efficiency goals with robust impurity removal, maximize downstream recovery, and ensure patient safety. Merck’s integrated portfolio, regulatory and applications expertise can help address these process challenges.
Viral Vector Vaccine Manufacturing
A relatively templated manufacturing process can be used to produce live vector vaccines. Challenges exist, however, and include yield loss due to sterile filtration, vector aggregation and scaling adherent cultures. Learn all about this core platform technology and how expertise—empowered
BIO International
We warmly invite you to visit booth 4735 at BIO International and connect with the MilliporeSigma team.
Cost Modeling Vaccine Manufacturing: Estimate Production Costs for mRNA and other Vaccine Modalities
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.